"Nov. 20, 2012 -- Oral contraceptives should be made available without a prescription to reduce unintended pregnancies, according to a newly published opinion by the American College of Obstetricians and Gynecologists (ACOG).
Patients should be counseled that this product does not protect against HIV infection (AIDS) or other sexually transmitted diseases.
Jadelle® (levonorgestrel implants unavailable in us) is a set of two flexible cylindrical implants, consisting of a dimethylsiloxane/ methylvinylsiloxane copolymer core enclosed in thin-walled silicone tubing. Each implant contains 75 mg of the progestin levonorgestrel. The implants are sealed with polydimethylsiloxane adhesive and sterilized. Each implant is approximately 2.5 mm in diameter and 43 mm in length. The implants are inserted in a superficial plane beneath the skin of the upper arm.
The calculated mean daily in vivo release rate of levonorgestrel provided by the implants is about 100 µg/day at month 1 followed by a decline to about 40 µg/day at 12 months and to about 30 µg/day at 24 months with a stabilization thereafter at about 30 µg/day.
Jadelle® (levonorgestrel implants unavailable in us) implants are a progestin-only product and do not contain estrogen. The active ingredient in the implants is levonorgestrel, (-)-13-ethyl-17-hydroxy-18,19-dinor-17α-pregn-4-en-20-yn-3-one. It has a molecular weight of 312.45 and the following structural formula:
Last reviewed on RxList: 12/29/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Jadelle Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.